Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study
Loading...
Date
Authors
Kalofonos, H. P.
Kardamakis, D.
Bamias, A.
Skarlos, D.
Papakostas, P.
Bafaloukos, D.
Sakantamis, A.
Pavlidis, N.
Fountzilas, G.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Anticancer Res
Book name
Book series
Book edition
Alternative title / Subtitle
Description
BACKGROUND: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied the toxicity profile of postoperatively administered CPT-11 plus leucovorin (LV)-modulated 5FU and radiotherapy in patients with rectal cancer. PATIENTS AND METHODS: Thirty-seven patients with Dukes' B2 and C rectal adenocarcinoma were treated with CPT-11, 80 mg/m2 ii.v. over 90 minutes followed by LV 200 mg/m2 over 2 hours and 5FU 450 mg/m2 i.v.-bolus weekly for 4 weeks followed by a 2-week rest period. One cycle included 4 infusions. The first cycle of chemotherapy was followed by pelvic radiation to a total dose of 45 Gy to the whole pelvis and a boost of 5 Gy to the tumor bed. 5FU was administered daily as a rapid infusion during the first 3 as well as the last 3 days of radiotherapy. CPT-11 plus LV-modulated 5FU was continued for a total of 6 cycles or consent withdrawal. RESULTS: The main toxicity was reversible diarrhea (grade 3 and 4) in 9 (26%) patients during chemotherapy and in 3 (9%) patients during chemoradiotherapy. Furthermore, grade 3 leucopenia in 2 (6%) and 1 (3%) patient was observed during chemotherapy and chemoradiotherapy, respectively. CONCLUSION: This study provides evidence that adjuvant therapy using CPT-11 plus LV modulated 5FU and radiotherapy can be used in patients with rectal cancer.
Description
Keywords
Adenocarcinoma/*drug therapy/pathology/*radiotherapy/surgery, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Camptothecin/administration & dosage/adverse effects/*analogs & derivatives, Chemotherapy, Adjuvant/adverse effects, Feasibility Studies, Female, Fluorouracil/administration & dosage/adverse effects, Humans, Leucovorin/administration & dosage/adverse effects, Male, Middle Aged, Neoplasm Staging, Radiotherapy, Adjuvant/adverse effects, Rectal Neoplasms/*drug therapy/pathology/*radiotherapy/surgery
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/12820441
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής